| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
6645 Stock Overview
Kim Forest Enterprise Co., Ltd. provides precision medical products.
Kim Forest Enterprise Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$36.90 |
| 52 Week High | NT$46.31 |
| 52 Week Low | NT$22.35 |
| Beta | -0.44 |
| 1 Month Change | 2.61% |
| 3 Month Change | -6.85% |
| 1 Year Change | 31.69% |
| 3 Year Change | 118.43% |
| 5 Year Change | n/a |
| Change since IPO | 71.22% |
Recent News & Updates
Shareholder Returns
| 6645 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 0.1% | -1.3% | 0.1% |
| 1Y | 31.7% | 33.4% | -14.4% |
Return vs Industry: 6645 underperformed the TW Biotechs industry which returned 33.4% over the past year.
Return vs Market: 6645 exceeded the TW Market which returned -14.4% over the past year.
Price Volatility
| 6645 volatility | |
|---|---|
| 6645 Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in TW Market | 8.4% |
| 10% least volatile stocks in TW Market | 2.5% |
Stable Share Price: 6645 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: 6645's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | n/a | https://www.kimforest.com |
Kim Forest Enterprise Co., Ltd. provides precision medical products. It offers devices, reagents, and analysis pipelines to health care providers, which include screening tests for cancer and inherited diseases. The company also provides genetic testing, drug report, and monitoring tools for cancer patients; and a non-invasive genome-wide health assessment for healthy persons.
Kim Forest Enterprise Fundamentals Summary
| 6645 fundamental statistics | |
|---|---|
| Market Cap | NT$1.49b |
| Earnings (TTM) | NT$89.44m |
| Revenue (TTM) | NT$600.67m |
16.6x
P/E Ratio2.5x
P/S RatioIs 6645 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6645 income statement (TTM) | |
|---|---|
| Revenue | NT$600.67m |
| Cost of Revenue | NT$341.20m |
| Gross Profit | NT$259.47m |
| Other Expenses | NT$170.03m |
| Earnings | NT$89.44m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.22 |
| Gross Margin | 43.20% |
| Net Profit Margin | 14.89% |
| Debt/Equity Ratio | 13.6% |
How did 6645 perform over the long term?
See historical performance and comparisonDividends
0.5%
Current Dividend Yield9%
Payout RatioValuation
Is 6645 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6645?
Other financial metrics that can be useful for relative valuation.
| What is 6645's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | NT$1.49b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.3x |
| Enterprise Value/EBITDA | 10.9x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 6645's PE Ratio compare to its peers?
| 6645 PE Ratio vs Peers |
|---|
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 54.1x | ||
4117 General Biologicals | 34.6x | n/a | NT$1.5b |
4195 Genomics BioSci & Tech.Ltd | 60.5x | n/a | NT$1.1b |
1780 Allied Biotech | 100.9x | n/a | NT$1.3b |
3164 GenMont Biotech Incorporation | 20.4x | n/a | NT$2.2b |
6645 Kim Forest Enterprise | 16.6x | n/a | NT$1.5b |
Price-To-Earnings vs Peers: 6645 is good value based on its Price-To-Earnings Ratio (16.6x) compared to the peer average (54.1x).
Price to Earnings Ratio vs Industry
How does 6645's PE Ratio compare vs other companies in the Asian Biotechs Industry?
Price-To-Earnings vs Industry: 6645 is good value based on its Price-To-Earnings Ratio (16.6x) compared to the TW Biotechs industry average (32.8x)
Price to Earnings Ratio vs Fair Ratio
What is 6645's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 16.6x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6645's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 6645 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 6645 (NT$36.9) is trading below our estimate of fair value (NT$394.81)
Significantly Below Fair Value: 6645 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Future Growth
How is Kim Forest Enterprise forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
148.0%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kim Forest Enterprise has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether Kim Forest Enterprise is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
Past Performance
How has Kim Forest Enterprise performed over the past 5 years?
Past Performance Score
3/6Past Performance Score 3/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
15.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6645 has high quality earnings.
Growing Profit Margin: 6645 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 6645 has become profitable over the past 5 years, growing earnings by 15.4% per year.
Accelerating Growth: 6645 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 6645 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-29%).
Return on Equity
High ROE: 6645's Return on Equity (16.6%) is considered low.
Discover strong past performing companies
Financial Health
How is Kim Forest Enterprise's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: 6645's short term assets (NT$404.1M) exceed its short term liabilities (NT$133.7M).
Long Term Liabilities: 6645's short term assets (NT$404.1M) exceed its long term liabilities (NT$67.3M).
Debt to Equity History and Analysis
Debt Level: 6645 has more cash than its total debt.
Reducing Debt: 6645's debt to equity ratio has reduced from 78.9% to 13.6% over the past 5 years.
Debt Coverage: 6645's debt is well covered by operating cash flow (121.4%).
Interest Coverage: 6645's interest payments on its debt are well covered by EBIT (85.4x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is Kim Forest Enterprise current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
0.52%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 6645's dividend (0.52%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (2.55%).
High Dividend: 6645's dividend (0.52%) is low compared to the top 25% of dividend payers in the TW market (6.64%).
Stability and Growth of Payments
Stable Dividend: 6645 is not paying a notable dividend for the TW market, therefore no need to check if payments are stable.
Growing Dividend: 6645 is not paying a notable dividend for the TW market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: 6645 is not paying a notable dividend for the TW market.
Cash Payout to Shareholders
Cash Flow Coverage: 6645 is not paying a notable dividend for the TW market.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Kim Forest Enterprise has no CEO, or we have no data on them.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Kim Forest Enterprise Co., Ltd.'s employee growth, exchange listings and data sources
Key Information
- Name: Kim Forest Enterprise Co., Ltd.
- Ticker: 6645
- Exchange: TPEX
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: NT$1.487b
- Shares outstanding: 40.30m
- Website: https://www.kimforest.com
Number of Employees
Location
- Kim Forest Enterprise Co., Ltd.
- No. 97, Xintai 5th Road
- 30th Floor
- New Taipei City
- 221
- Taiwan
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/07 00:00 |
| End of Day Share Price | 2022/08/05 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.